Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 1/20 | 0.58 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.58 |
| ▸ | BRD4 | O60885 | 1/20 | 0.53 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.46 |
| ▸ | HTR7 | P34969 | 1/20 | 0.44 |
| ▸ | USP7 | Q93009 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17377137 | 1.00 | PRMT5 (0.58) | PRMT5WDR77BRD4CREBBPLMNA | |
| SCHEMBL19164201 | 0.84 | PRMT5 (0.71) | PRMT5WDR77BRD4CREBBP | |
| SCHEMBL17877207 | 0.78 | BRD4 (0.56) | BRD4CREBBPLMNAMAPK10HTR7 | |
| SCHEMBL17877240 | 0.76 | DRD4 (0.58) | BRD4CREBBPLMNAMAPK10HTR7 | |
| SCHEMBL13068445 | 0.74 | HTR7 (0.59) | BRD4CREBBPLMNAMAPK10HTR7 | |
| SCHEMBL17377061 | 0.74 | CTSS (0.42) | PRMT5WDR77CREBBP | |
| SCHEMBL15943876 | 0.74 | PRMT5 (1.00) | PRMT5WDR77 | |
| SCHEMBL17377018 | 0.74 | PRMT5 (0.52) | PRMT5WDR77 | |
| SCHEMBL17377019 | 0.74 | PRMT5 (0.52) | PRMT5WDR77 | |
| SCHEMBL22528271 | 0.73 | ACHE (0.61) | PRMT5WDR77LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170210751-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-07-27 | — | — | US | disclosed |
| US-20170210751-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-07-27 | — | — | US | disclosed |
| US-20170210751-A1 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-07-27 | — | — | US | disclosed |
| EP-3160466-A2 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2017-05-03 | — | — | EP | disclosed |
| WO-2015200677-A2 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2015-12-30 | — | — | WO | disclosed |
| WO-2015200677-A2 | PRMT5 INHIBITORS AND USES THEREOF | Epizyme, Inc. (US) | 2015-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170210751-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT6 | PRMT5 1/4885WDR77 68/4885BRD4 122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.